Anti-RPL7A Rabbit Polyclonal Antibody for WB, IF/ICC, ELISA - P62424

Core Product Specifications and Parameters

Biological Background: RPL7A Function and Localization

• RPL7A encodes the large ribosomal subunit protein eL8, also designated 60S ribosomal protein L7a, PLA‑X polypeptide, or surfeit locus protein 3.
• It is a core component of the large ribosomal subunit, a ribonucleoprotein complex that catalyzes protein synthesis in all cells.
  Related references: PMID:23636399 PMID:32669547
• The protein belongs to the universal ribosomal protein L7Ae family and shares homology across eukaryotes and archaea.
• RPL7A is predominantly localized to the cytoplasm, where it participates in translation.
• Post‑translational modifications include N‑terminal acetylation and ubiquitin‑like (Ubl) conjugation, which may regulate ribosome function or turnover.
• Structural studies (3D‑structure) have detailed its integration into the ribosomal architecture, and chromosomal rearrangements involving the RPL7A locus have been reported in certain malignancies.

Experimental Guidance and Technical Tips

• This antibody was generated against recombinant full‑length human RPL7A (aa 1‑266). For western blotting (WB), the predicted molecular weight is ~30 kDa; consider appropriate gel percentages and membrane transfer conditions.
• In immunofluorescence/immunocytochemistry (IF/ICC), fixation and permeabilization steps should be optimized for the target cell or tissue system to ensure epitope accessibility.
• ELISA suitability is indicated; users should determine optimal coating antigen and antibody titration in their specific assay format.
• Cross‑reactivity with mouse and rat has been confirmed; when working with these species, validate in the relevant sample system to confirm comparable specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with reliable access to IVD raw materials, including anti‑RPL7A antibodies and related ribosomal targets. Our portfolio spans validated antibody pairs, optimized polyclonal and monoclonal reagents, and bulk ancillary supplies, enabling smooth transition from concept to clinic. For customized sourcing or technical consultation on rare‑target antibodies and assay development, our team offers comprehensive support tailored to your project needs.